On 15 June 2021, the sale of NutraQ to Orkla Health was completed after approval from all relevant competition authorities. NutraQ is a leading supplier of subscription-based health and wellness products in the Nordic region. The company was established in Norway in 2002 and at Impilo’s entry in 2017, the company had a strong presence in Norway, Sweden, Finland, Czech Republic and an emerging presence in Denmark.
Impilo’s divestment of NutraQ to Orkla completed On 15 June 2021, the sale of NutraQ to Orkla Health was completed after approval from all relevant competition authorities.
NutraQ is a leading supplier of subscription-based health and wellness products in the Nordic region. The company was established in Norway in 2002 and at Impilo’s entry in 2017, the company had a strong presence in Norway, Sweden, Finland, Czech Republic and an emerging presence in Denmark.
“We are highly impressed by the achievements and execution abilities of the NutraQ organization – led by CEO Gustaf S Christensen – transforming the company from a successful founder led Nordic D2C business into a world-class, data driven and digitalized D2C platform across several Northern European markets”, says Magnus Edlund, partner at Impilo.
During Impilo’s ownership, the company has expanded its footprint significantly – both geographically and concept-wise – alongside with an enhanced professionalization and digitalization of operations. Over the past three years, revenues and earnings have grown w. ca. 20% and 30% per year, respectively, with continued strong momentum in 2021.
“NutraQ’s management was given a clear mandate from its owners and board of directors to accelerate growth, operational efficiency, and geographical expansion and it has been a pleasure to lead that effort. NutraQ is today a high performing D2C platform – and with Orkla as a new owner – we can further accelerate our plans to expand geographically and across new product categories” says Gustaf S Christensen, CEO of NutraQ.
“The combination of an active ownership model deployed by the partnership between Impilo and NutraQ’s founders and strong independent board members formed an effective governance model during a very busy transformational period. I am convinced that Orkla is an ideal new home for the business, perfectly fit to support NutraQ’s continued development.” says Henning Søgaard, Chairman of the Board since 2018.
News
Impilo’s portfolio company Decon acquires Acekare – a French-based manufacturer and distributor of mobility assistance solutions
The acquisition of Acekare marks an important step in Decon’s strategic ambition to build a leading European niche mobility platform by adding a complementary product company to its existing offering and establishing a direct presence in the French market
Impilo’s portfolio company Pelago Bioscience acquires RG Discovery, forming an integrated drug discovery partner spanning biology and chemistry
Impilo’s portfolio company Pelago Bioscience acquires RG Discovery, forming an integrated drug discovery partner spanning biology and chemistry
Impilo completes the acquisition of Oticon Medical
We are pleased to announce that Impilo has today completed the acquisition of Oticon Medical from Demant A/S. This marks the first investment in our recently raised Fund II.